B
Brandon Doyle
Researcher at Eli Lilly and Company
Publications - 12
Citations - 531
Brandon Doyle is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Analytical Ultracentrifugation & Protein arginine methyltransferase 5. The author has an hindex of 7, co-authored 12 publications receiving 469 citations.
Papers
More filters
Journal ArticleDOI
Crystal structure of the human PRMT5:MEP50 complex
Stephen Antonysamy,Zahid Quyoom Bonday,Robert M. Campbell,Brandon Doyle,Zhanna Druzina,Tarun Gheyi,Bomie Han,Louis Nickolaus Jungheim,Yuewei Qian,Charles Rauch,Marijane Russell,J. Michael Sauder,S.R. Wasserman,Kenneth Weichert,Francis S. Willard,Aiping Zhang,S. Emtage +16 more
TL;DR: The crystal structure of human PRMT5 in complex with MEP50, bound to an S-adenosylmethionine analog and a peptide substrate derived from histone H4 is determined and the structure of the surprising hetero-octameric complex reveals the close interaction between the seven-bladed β-propeller MEP50 and the N-terminal domain ofPRMT5, and delineates the structural elements of substrate recognition.
Journal ArticleDOI
Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association.
TL;DR: The results indicate that opalescent appearance is not due to self-association but is a simple consequence of Rayleigh scatter, and did not result in physical instability.
Patent
Pegylated insulin lispro compounds
John Michael Beals,Gordon B. Cutler,Brandon Doyle,Ryan John Hansen,Shun Li,Shahriar Shirani,Lianshan Zhang +6 more
TL;DR: In this paper, PEGylated insulin lispro compounds are defined as insulin compounds with high molecular weight poly(ethylene glycol) and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2.
Journal ArticleDOI
Characterization of a cathepsin D protease from CHO cell-free medium and mitigation of its impact on the stability of a recombinant therapeutic protein.
Amareth Lim,Brandon Doyle,Gerard M. Kelly,Angelia Reed-Bogan,Lawrence H. Breen,Parviz Ayazi Shamlou,Peter K. Lambooy +6 more
TL;DR: The identification and characterization of this protease enabled the development of a robust purification process by implementation of a controlled temperature inactivation unit operation (heat inactivation) that enabled essentially complete inactivation of the protease, resulting in the production of a stable drug product that had not been possible using column chromatography alone.
Journal ArticleDOI
Technical Decision-Making with Higher Order Structure Data: Specific Binding of a Nonionic Detergent Perturbs Higher Order Structure of a Therapeutic Monoclonal Antibody
TL;DR: The utility of several orthogonal HOS methods as investigational tools during purification process development and the importance of HOS characterization as a component of overall biopharmaceutical analytical control strategy are underlined.